NCT06226350View on ClinicalTrials.gov

A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 4, 2021

Primary Completion Date

December 5, 2023

Study Completion Date

January 3, 2024

Conditions

Cervical Cancer

Interventions

DRUG

Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection

F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.

Trial Locations (1)

Unknown

Shandong New Time Pharmaceutical Co., LTD, Shandong

All Listed Sponsors

lead

Shandong New Time Pharmaceutical Co., LTD

INDUSTRY

NCT06226350 - A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma | Biotech Hunter | Biotech Hunter